1.29
Stereotaxis Inc stock is traded at $1.29, with a volume of 350.57K.
It is down -2.27% in the last 24 hours and down -9.15% over the past month.
Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic magnetic navigation system that enables physicians to complete interventional procedures by providing image guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and therapeutic devices designed to enhance interventional procedures. The company also offers Odyssey solution, a real-time information solution to manage, control, record, and share procedures across networks. In addition, it provides disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company's disposables and other accessories include V-CAS and V-CAS Deflect catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. The company markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to design and develop a next-generation magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.
See More
Previous Close:
$1.32
Open:
$1.33
24h Volume:
350.57K
Relative Volume:
0.42
Market Cap:
$129.26M
Revenue:
$31.20M
Net Income/Loss:
$-21.68M
P/E Ratio:
-5.2826
EPS:
-0.2442
Net Cash Flow:
$-15.52M
1W Performance:
+0.00%
1M Performance:
-9.15%
6M Performance:
-28.33%
1Y Performance:
-55.97%
Stereotaxis Inc Stock (STXS) Company Profile
Name
Stereotaxis Inc
Sector
Industry
Phone
314-678-6100
Address
4320 Forest Park Avenue, Suite 100, St. Louis, MO
Compare STXS vs ISRG, BDX, RMD, ALC, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
STXS
Stereotaxis Inc
|
1.29 | 129.26M | 31.20M | -21.68M | -15.52M | -0.2442 |
|
ISRG
Intuitive Surgical Inc
|
399.52 | 141.14B | 11.03B | 3.16B | 3.22B | 8.7251 |
|
BDX
Becton Dickinson Co
|
179.23 | 48.82B | 21.37B | 1.41B | 3.07B | 3.9437 |
|
RMD
Resmed Inc
|
221.89 | 32.01B | 5.54B | 1.52B | 1.74B | 10.37 |
|
ALC
Alcon Inc
|
64.56 | 31.21B | 10.63B | 819.00M | 1.59B | 1.6577 |
|
MDLN
Medline Inc
|
34.66 | 30.41B | 29.14B | 1.07B | 1.05B | 1.1956 |
Stereotaxis Inc Stock (STXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jan-10-24 | Initiated | ROTH MKM | Buy |
| Jul-12-22 | Initiated | Aegis Capital | Buy |
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Jan-05-22 | Initiated | Craig Hallum | Buy |
| Jan-05-22 | Initiated | Loop Capital | Buy |
| May-26-21 | Initiated | Piper Sandler | Overweight |
| Sep-08-20 | Initiated | Northland Capital | Outperform |
| Apr-09-20 | Initiated | Cowen | Outperform |
| Apr-07-20 | Initiated | Lake Street | Buy |
View All
Stereotaxis Inc Stock (STXS) Latest News
Stereotaxis Inc. Share PriceSTXS, RNS News, Articles, Quotes, & Charts (NYSEMKT:STXS) - Proactive financial news
Stereotaxis Inc. (STXS) Stock Price | Live Quotes & Charts | AMEX - StocksToTrade
Stereotaxis Stock Price Forecast. Should You Buy STXS? - StockInvest.us
Stereotaxis, Inc. Features Synchrony And SynX Digital Technologies At Heart Rhythm Society?s HRX Conference - marketscreener.com
Stereotaxis Flat Ahead of Atlanta Heart Conference - Baystreet.ca
Stereotaxis Emerging Digital, AI and Automation Capabilities to be Featured at Heart Rhythm Society’s HRX 2026 - GlobeNewswire
Earnings Preview: Stereotaxis to Report Financial Results Post-market on August 11 - Moomoo
Stereotaxis: A Real Product Story, But The Stock Already Prices In Success (NYSE:STXS) - Seeking Alpha
July launch by Stereotaxis achieves 70 cases treating full arrhythmia spectrum - Traders Union
A Hungarian hospital treated over 70 heart patients with robots in just over a month - Stock Titan
Stereotaxis Inc (STXS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Citizens lowers Stereotaxis stock price target to $3 on guidance cut - Investing.com Canada
Citizens JMP Maintains Stereotaxis(STXS.US) With Buy Rating, Cuts Target Price to $3 - moomoo.com
STXS | Stereotaxis, Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Stereotaxis (STXS) Q2 2026 Earnings Call Transcript - AOL.com
Stereotaxis (STXS) Update: Ends Lower by 1.39% at $1.42 in the Current Update; Market Levels: the $1.35 to $1.49 Range Remains in Focus at the ClosePut Wall - dars.gov.et
New >5% shareholder emerges in Stereotaxis (STXS) stock - Stock Titan
Stereotaxis, Inc. momentum grows in robotic electrophysiology as sector approaches inflection point - Traders Union
Robot performs 26 cataract surgeries with surgeon control - AOL.com
STXS|Stereotaxis Inc|Price:1.395|Chg%:+0.035 - TradingKey
Stereotaxis Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Stereotaxis, Inc. engages with medical leaders at KCHRS event - Traders Union
Stereotaxis, Inc. introduces MAGiC ablation tip for efficient energy delivery - Traders Union
Stereotaxis, Inc. SEC Filing (Aug 14, 2026) - Stock Titan
Stereotaxis (STXS) Stock Sees Little Reward For Recurring Revenue Progress - Sahm
STXS Q2 2026 Earnings: Narrow EPS Beat Overshadowed by 4.11% Share SlideTangible Book Value - vinanet.vn
Stereotaxis, Inc. completes Robocath deal as GenesisX gains first U.S. customer - Traders Union
Stereotaxis, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Stereotaxis Q2 Earnings Call Highlights - TradingView
Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Is Stereotaxis Inc (STXS) Undervalued Despite Q2 Revenue Miss? G - GuruFocus
Stereotaxis robotic catheter sales surge 270% in Q2 despite revenue miss - scanx.trade
Transcript : Stereotaxis, Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com
Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates - The Manila Times
Stereotaxis Q2 revenue misses estimates, dragged by system decline - tradingview.com
Stereotaxis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Stereotaxis’ First U.S. GenesisX Robot to Be Installed This Fall - Stock Titan
BRIEF-Stereotaxis Q2 Revenue USD 7.67 Million Vs. IBES Estimate USD 8.35 Million - TradingView
Stereotaxis Inc (STXS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Stereotaxis Inc (RJR1.DU) Analyst insights, Price targets and Recommendations - Yahoo Finance Australia
Enterprise value to revenue forward of Stereotaxis, Inc. – FWB:RJR1 - TradingView
Stereotaxis, Inc. brings GenesisX robot for community heart health education in St. Louis - tradersunion.com
Stereotaxis (STXS) Projected to Release Quarterly Earnings on Tuesday - marketbeat.com
Stereotaxis Inc (STXS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Stereotaxis Inc (STXS) Institutional Confidence - TradingKey
STXS Q1 2026 Earnings: EPS Misses Estimates Amid Limited Financial VisibilityHealthcare Earnings Report - vinanet.vn
Stereotaxis Inc (STXS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Stereotaxis Inc (STXS) Cash Flow - TradingKey
Stereotaxis Inc (STXS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Stereotaxis Inc (STXS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
STXS|Stereotaxis Inc|Price:1.260|Chg%:-0.070 - TradingKey
Stereotaxis Inc Stock (STXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):